APO Research
Talk to an analyst

APO RESEARCH · REPORT

Biocompatibility Testing

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Biocompatibility Testing Market Outlook and Growth Opportunities 2026

3 May 2026194 pages

Choose your research edition.

Industry ResearchBiocompatibility Testing Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Biocompatibility Testing Industry Growth and Trends Forecast to 2032123 pages · $3,450 USDMarket StructureGlobal Biocompatibility Testing Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Biocompatibility Testing Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Biocompatibility Testing Market Analysis and Forecast 2026-2032184 pages · $4,950 USD

Market perspective

The global Biocompatibility Testing market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Biocompatibility Testing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Biocompatibility Testing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Biocompatibility Testing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Biocompatibility Testing market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Biocompatibility Testing market include Eurofins, Charles River, TUV SUD, Intertek Group, WuXi AppTec, LabCorp, Syensqo, SGS and Nelson Labs, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Biocompatibility Testing market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Biocompatibility Testing and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Biocompatibility Testing revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Biocompatibility Testing market.

Biocompatibility Testing Segment by Company

Eurofins

Charles River

TUV SUD

Intertek Group

WuXi AppTec

LabCorp

Syensqo

SGS

Nelson Labs

Pacific BioLabs

Vantage MedTech

Cormica Lab (Wickham Micro)

CTI

CIRS

Shenzhen Advanced

Kerbio

CAS Testing

PONY Medicine

Tigermed

King Rock

Biocompatibility Testing Segment by Type

Cytotoxicity

Sensitization

Irritant

Pyrogen

Other

Biocompatibility Testing Segment by Application

Clinical

Non-clinical

Biocompatibility Testing Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Biocompatibility Testing status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Biocompatibility Testing key companies, revenue, market share, and recent developments.

3. To split the Biocompatibility Testing breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Biocompatibility Testing market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Biocompatibility Testing significant trends, drivers, influence factors in global and regions.

6. To analyze Biocompatibility Testing competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biocompatibility Testing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Biocompatibility Testing and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biocompatibility Testing.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Biocompatibility Testing industry.

Chapter 3: Detailed analysis of Biocompatibility Testing company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Biocompatibility Testing in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Biocompatibility Testing in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Biocompatibility Testing Industry Trends Table 2. Biocompatibility Testing Industry Drivers Table 3. Biocompatibility Testing Industry Opportunities and Challenges Table 4. Biocompatibility Testing Industry Restraints Table 5. Global Biocompatibility Testing Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Biocompatibility Testing Revenue Share by Company (2021-2026) Table 7. Global Biocompatibility Testing Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Biocompatibility Testing Key Company Manufacturing Base & Headquarters Table 9. Global Biocompatibility Testing Company, Product Type & Application Table 10. Global Biocompatibility Testing Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Biocompatibility Testing by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Cytotoxicity Table 15. Significant Companies of Sensitization Table 16. Significant Companies of Irritant Table 17. Significant Companies of Pyrogen Table 18. Significant Companies of Other Table 19. Global Biocompatibility Testing Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global Biocompatibility Testing Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global Biocompatibility Testing Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global Biocompatibility Testing Sales Value Share by Type (2021-2026) Table 23. Global Biocompatibility Testing Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Clinical Table 25. Significant Companies of Non-clinical Table 26. Global Biocompatibility Testing Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Biocompatibility Testing Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Biocompatibility Testing Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Biocompatibility Testing Sales Value Share by Application (2021-2026) Table 30. Global Biocompatibility Testing Sales Value Share by Application (2027-2032) Table 31. Global Biocompatibility Testing Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Biocompatibility Testing Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Biocompatibility Testing Sales Value Share by Region (2021-2026) Table 34. Global Biocompatibility Testing Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Biocompatibility Testing Sales Value Share by Region (2027-2032) Table 36. Global Biocompatibility Testing Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Biocompatibility Testing Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Biocompatibility Testing Sales Value Market Share by Country (2021-2026) Table 39. Global Biocompatibility Testing Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Biocompatibility Testing Sales Value Market Share by Country (2027-2032) Table 41. Eurofins Company Information Table 42. Eurofins Business Overview Table 43. Eurofins Biocompatibility Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Eurofins Biocompatibility Testing Product Portfolio Table 45. Eurofins Recent Development Table 46. Charles River Company Information Table 47. Charles River Business Overview Table 48. Charles River Biocompatibility Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Charles River Biocompatibility Testing Product Portfolio Table 50. Charles River Recent Development Table 51. TUV SUD Company Information Table 52. TUV SUD Business Overview Table 53. TUV SUD Biocompatibility Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. TUV SUD Biocompatibility Testing Product Portfolio Table 55. TUV SUD Recent Development Table 56. Intertek Group Company Information Table 57. Intertek Group Business Overview Table 58. Intertek Group Biocompatibility Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Intertek Group Biocompatibility Testing Product Portfolio Table 60. Intertek Group Recent Development Table 61. WuXi AppTec Company Information Table 62. WuXi AppTec Business Overview Table 63. WuXi AppTec Biocompatibility Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. WuXi AppTec Biocompatibility Testing Product Portfolio Table 65. WuXi AppTec Recent Development Table 66. LabCorp Company Information Table 67. LabCorp Business Overview Table 68. LabCorp Biocompatibility Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. LabCorp Biocompatibility Testing Product Portfolio Table 70. LabCorp Recent Development Table 71. Syensqo Company Information Table 72. Syensqo Business Overview Table 73. Syensqo Biocompatibility Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Syensqo Biocompatibility Testing Product Portfolio Table 75. Syensqo Recent Development Table 76. SGS Company Information Table 77. SGS Business Overview Table 78. SGS Biocompatibility Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. SGS Biocompatibility Testing Product Portfolio Table 80. SGS Recent Development Table 81. Nelson Labs Company Information Table 82. Nelson Labs Business Overview Table 83. Nelson Labs Biocompatibility Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Nelson Labs Biocompatibility Testing Product Portfolio Table 85. Nelson Labs Recent Development Table 86. Pacific BioLabs Company Information Table 87. Pacific BioLabs Business Overview Table 88. Pacific BioLabs Biocompatibility Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Pacific BioLabs Biocompatibility Testing Product Portfolio Table 90. Pacific BioLabs Recent Development Table 91. Vantage MedTech Company Information Table 92. Vantage MedTech Business Overview Table 93. Vantage MedTech Biocompatibility Testing Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 94. Vantage MedTech Biocompatibility Testing Product Portfolio Table 95. Vantage MedTech Recent Development Table 96. Cormica Lab (Wickham Micro) Company Information Table 97. Cormica Lab (Wickham Micro) Business Overview Table 98. Cormica Lab (Wickham Micro) Biocompatibility Testing Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 99. Cormica Lab (Wickham Micro) Biocompatibility Testing Product Portfolio Table 100. Cormica Lab (Wickham Micro) Recent Development Table 101. CTI Company Information Table 102. CTI Business Overview Table 103. CTI Biocompatibility Testing Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 104. CTI Biocompatibility Testing Product Portfolio Table 105. CTI Recent Development Table 106. CIRS Company Information Table 107. CIRS Business Overview Table 108. CIRS Biocompatibility Testing Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 109. CIRS Biocompatibility Testing Product Portfolio Table 110. CIRS Recent Development Table 111. Shenzhen Advanced Company Information Table 112. Shenzhen Advanced Business Overview Table 113. Shenzhen Advanced Biocompatibility Testing Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 114. Shenzhen Advanced Biocompatibility Testing Product Portfolio Table 115. Shenzhen Advanced Recent Development Table 116. Kerbio Company Information Table 117. Kerbio Business Overview Table 118. Kerbio Biocompatibility Testing Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 119. Kerbio Biocompatibility Testing Product Portfolio Table 120. Kerbio Recent Development Table 121. CAS Testing Company Information Table 122. CAS Testing Business Overview Table 123. CAS Testing Biocompatibility Testing Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 124. CAS Testing Biocompatibility Testing Product Portfolio Table 125. CAS Testing Recent Development Table 126. PONY Medicine Company Information Table 127. PONY Medicine Business Overview Table 128. PONY Medicine Biocompatibility Testing Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 129. PONY Medicine Biocompatibility Testing Product Portfolio Table 130. PONY Medicine Recent Development Table 131. Tigermed Company Information Table 132. Tigermed Business Overview Table 133. Tigermed Biocompatibility Testing Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 134. Tigermed Biocompatibility Testing Product Portfolio Table 135. Tigermed Recent Development Table 136. King Rock Company Information Table 137. King Rock Business Overview Table 138. King Rock Biocompatibility Testing Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 139. King Rock Biocompatibility Testing Product Portfolio Table 140. King Rock Recent Development Table 141. Research Programs/Design for This Report Table 142. Authors List of This Report Table 143. Secondary Sources Table 144. Primary Sources List of Figures Figure 1. Biocompatibility Testing Product Image Figure 2. Global Biocompatibility Testing Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Biocompatibility Testing Market Size (2021-2032) & (US$ Million) Figure 4. Global Biocompatibility Testing Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Cytotoxicity Image Figure 8. Sensitization Image Figure 9. Irritant Image Figure 10. Pyrogen Image Figure 11. Other Image Figure 12. Global Biocompatibility Testing Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global Biocompatibility Testing Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global Biocompatibility Testing Sales Value Share by Type (2021-2032) Figure 15. Clinical Image Figure 16. Non-clinical Image Figure 17. Global Biocompatibility Testing Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Biocompatibility Testing Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Biocompatibility Testing Sales Value Share by Application (2021-2032) Figure 20. Global Biocompatibility Testing Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Biocompatibility Testing Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Biocompatibility Testing Sales Value (2021-2032) & (US$ Million) Figure 23. North America Biocompatibility Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Biocompatibility Testing Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Biocompatibility Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Biocompatibility Testing Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Biocompatibility Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Biocompatibility Testing Sales Value (2021-2032) & (US$ Million) Figure 29. South America Biocompatibility Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Biocompatibility Testing Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Biocompatibility Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Biocompatibility Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Biocompatibility Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Biocompatibility Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Biocompatibility Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Biocompatibility Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Biocompatibility Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Biocompatibility Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Biocompatibility Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Biocompatibility Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Biocompatibility Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Biocompatibility Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Biocompatibility Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Biocompatibility Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Biocompatibility Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Biocompatibility Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Biocompatibility Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Biocompatibility Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Biocompatibility Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Biocompatibility Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Biocompatibility Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Biocompatibility Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Biocompatibility Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Biocompatibility Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Biocompatibility Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Biocompatibility Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Biocompatibility Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Biocompatibility Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Biocompatibility Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Biocompatibility Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Biocompatibility Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Biocompatibility Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Biocompatibility Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Biocompatibility Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Biocompatibility Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Biocompatibility Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Biocompatibility Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Biocompatibility Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Biocompatibility Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Biocompatibility Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Biocompatibility Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Biocompatibility Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Biocompatibility Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Biocompatibility Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Biocompatibility Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Biocompatibility Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Biocompatibility Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Biocompatibility Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Biocompatibility Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Biocompatibility Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Biocompatibility Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Biocompatibility Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Biocompatibility Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Biocompatibility Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Biocompatibility Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Biocompatibility Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Biocompatibility Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Biocompatibility Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Biocompatibility Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Biocompatibility Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Biocompatibility Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Biocompatibility Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Biocompatibility Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Biocompatibility Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Biocompatibility Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Biocompatibility Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Biocompatibility Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Biocompatibility Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Biocompatibility Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Biocompatibility Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Biocompatibility Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Biocompatibility Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Biocompatibility Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Biocompatibility Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Biocompatibility Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Biocompatibility Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Biocompatibility Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Biocompatibility Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Biocompatibility Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Biocompatibility Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Biocompatibility Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Biocompatibility Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Biocompatibility Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Biocompatibility Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Biocompatibility Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Cytotoxicity
  • Sensitization
  • Irritant
  • Pyrogen
  • Other
Applications
  • Clinical
  • Non-clinical
Companies covered
  • Eurofins
  • Charles River
  • TUV SUD
  • Intertek Group
  • WuXi AppTec
  • LabCorp
  • Syensqo
  • SGS
  • Nelson Labs
  • Pacific BioLabs
  • Vantage MedTech
  • Cormica Lab (Wickham Micro)
  • CTI
  • CIRS
  • Shenzhen Advanced
  • Kerbio
  • CAS Testing
  • PONY Medicine
  • Tigermed
  • King Rock

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Biocompatibility Testing Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Biocompatibility Testing Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Biocompatibility Testing Market Dynamics
  1. 2.1 Biocompatibility Testing Industry Trends
  2. 2.2 Biocompatibility Testing Industry Drivers
  3. 2.3 Biocompatibility Testing Industry Opportunities and Challenges
  4. 2.4 Biocompatibility Testing Industry Restraints
3 Biocompatibility Testing Market by Company
  1. 3.1 Global Biocompatibility Testing Company Revenue Ranking in 2025
  2. 3.2 Global Biocompatibility Testing Revenue by Company (2021-2026)
  3. 3.3 Global Biocompatibility Testing Company Ranking (2024-2026)
  4. 3.4 Global Biocompatibility Testing Company Manufacturing Base and Headquarters
  5. 3.5 Global Biocompatibility Testing Company Product Type and Application
  6. 3.6 Global Biocompatibility Testing Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Biocompatibility Testing Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Biocompatibility Testing Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Biocompatibility Testing Market by Type
  1. 4.1 Biocompatibility Testing Type Introduction
  2. 4.1.1 Cytotoxicity
  3. 4.1.2 Sensitization
  4. 4.1.3 Irritant
  5. 4.1.4 Pyrogen
  6. 4.1.5 Other
  7. 4.2 Global Biocompatibility Testing Sales Value by Type
  8. 4.2.1 Global Biocompatibility Testing Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Biocompatibility Testing Sales Value by Type (2021-2032)
  10. 4.2.3 Global Biocompatibility Testing Sales Value Share by Type (2021-2032)
5 Biocompatibility Testing Market by Application
  1. 5.1 Biocompatibility Testing Application Introduction
  2. 5.1.1 Clinical
  3. 5.1.2 Non-clinical
  4. 5.2 Global Biocompatibility Testing Sales Value by Application
  5. 5.2.1 Global Biocompatibility Testing Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Biocompatibility Testing Sales Value by Application (2021-2032)
  7. 5.2.3 Global Biocompatibility Testing Sales Value Share by Application (2021-2032)
6 Biocompatibility Testing Regional Value Analysis
  1. 6.1 Global Biocompatibility Testing Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Biocompatibility Testing Sales Value by Region (2021-2032)
  3. 6.2.1 Global Biocompatibility Testing Sales Value by Region: 2021-2026
  4. 6.2.2 Global Biocompatibility Testing Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Biocompatibility Testing Sales Value (2021-2032)
  7. 6.3.2 North America Biocompatibility Testing Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Biocompatibility Testing Sales Value (2021-2032)
  10. 6.4.2 Europe Biocompatibility Testing Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Biocompatibility Testing Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Biocompatibility Testing Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Biocompatibility Testing Sales Value (2021-2032)
  16. 6.6.2 South America Biocompatibility Testing Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Biocompatibility Testing Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Biocompatibility Testing Sales Value Share by Country, 2025 VS 2032
7 Biocompatibility Testing Country-level Value Analysis
  1. 7.1 Global Biocompatibility Testing Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Biocompatibility Testing Sales Value by Country (2021-2032)
  3. 7.2.1 Global Biocompatibility Testing Sales Value by Country (2021-2026)
  4. 7.2.2 Global Biocompatibility Testing Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Biocompatibility Testing Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Biocompatibility Testing Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Biocompatibility Testing Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Biocompatibility Testing Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Biocompatibility Testing Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Biocompatibility Testing Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Biocompatibility Testing Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Biocompatibility Testing Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Biocompatibility Testing Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Biocompatibility Testing Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Biocompatibility Testing Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Biocompatibility Testing Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Biocompatibility Testing Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Biocompatibility Testing Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Biocompatibility Testing Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Biocompatibility Testing Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Biocompatibility Testing Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Biocompatibility Testing Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Biocompatibility Testing Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Biocompatibility Testing Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Biocompatibility Testing Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Biocompatibility Testing Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Biocompatibility Testing Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Biocompatibility Testing Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Biocompatibility Testing Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Biocompatibility Testing Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Biocompatibility Testing Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Biocompatibility Testing Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Biocompatibility Testing Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Biocompatibility Testing Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Biocompatibility Testing Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Biocompatibility Testing Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Biocompatibility Testing Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Biocompatibility Testing Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Biocompatibility Testing Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Biocompatibility Testing Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Biocompatibility Testing Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Biocompatibility Testing Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Biocompatibility Testing Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Biocompatibility Testing Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Biocompatibility Testing Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Biocompatibility Testing Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Biocompatibility Testing Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Biocompatibility Testing Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Biocompatibility Testing Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Biocompatibility Testing Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Biocompatibility Testing Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Biocompatibility Testing Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Biocompatibility Testing Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Biocompatibility Testing Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Biocompatibility Testing Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Biocompatibility Testing Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Biocompatibility Testing Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Biocompatibility Testing Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Biocompatibility Testing Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Biocompatibility Testing Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Biocompatibility Testing Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Biocompatibility Testing Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Biocompatibility Testing Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Biocompatibility Testing Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Biocompatibility Testing Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Biocompatibility Testing Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Biocompatibility Testing Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Biocompatibility Testing Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Biocompatibility Testing Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Biocompatibility Testing Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Biocompatibility Testing Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Biocompatibility Testing Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Biocompatibility Testing Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Biocompatibility Testing Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Biocompatibility Testing Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Biocompatibility Testing Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Biocompatibility Testing Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Biocompatibility Testing Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Biocompatibility Testing Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Biocompatibility Testing Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Biocompatibility Testing Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Biocompatibility Testing Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Biocompatibility Testing Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Biocompatibility Testing Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Biocompatibility Testing Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Biocompatibility Testing Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Biocompatibility Testing Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Biocompatibility Testing Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Eurofins
  2. 8.1.1 Eurofins Company Information
  3. 8.1.2 Eurofins Business Overview
  4. 8.1.3 Eurofins Biocompatibility Testing Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Eurofins Biocompatibility Testing Product Portfolio
  6. 8.1.5 Eurofins Recent Developments
  7. 8.2 Charles River
  8. 8.2.1 Charles River Company Information
  9. 8.2.2 Charles River Business Overview
  10. 8.2.3 Charles River Biocompatibility Testing Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Charles River Biocompatibility Testing Product Portfolio
  12. 8.2.5 Charles River Recent Developments
  13. 8.3 TUV SUD
  14. 8.3.1 TUV SUD Company Information
  15. 8.3.2 TUV SUD Business Overview
  16. 8.3.3 TUV SUD Biocompatibility Testing Revenue and Gross Margin (2021-2026)
  17. 8.3.4 TUV SUD Biocompatibility Testing Product Portfolio
  18. 8.3.5 TUV SUD Recent Developments
  19. 8.4 Intertek Group
  20. 8.4.1 Intertek Group Company Information
  21. 8.4.2 Intertek Group Business Overview
  22. 8.4.3 Intertek Group Biocompatibility Testing Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Intertek Group Biocompatibility Testing Product Portfolio
  24. 8.4.5 Intertek Group Recent Developments
  25. 8.5 WuXi AppTec
  26. 8.5.1 WuXi AppTec Company Information
  27. 8.5.2 WuXi AppTec Business Overview
  28. 8.5.3 WuXi AppTec Biocompatibility Testing Revenue and Gross Margin (2021-2026)
  29. 8.5.4 WuXi AppTec Biocompatibility Testing Product Portfolio
  30. 8.5.5 WuXi AppTec Recent Developments
  31. 8.6 LabCorp
  32. 8.6.1 LabCorp Company Information
  33. 8.6.2 LabCorp Business Overview
  34. 8.6.3 LabCorp Biocompatibility Testing Revenue and Gross Margin (2021-2026)
  35. 8.6.4 LabCorp Biocompatibility Testing Product Portfolio
  36. 8.6.5 LabCorp Recent Developments
  37. 8.7 Syensqo
  38. 8.7.1 Syensqo Company Information
  39. 8.7.2 Syensqo Business Overview
  40. 8.7.3 Syensqo Biocompatibility Testing Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Syensqo Biocompatibility Testing Product Portfolio
  42. 8.7.5 Syensqo Recent Developments
  43. 8.8 SGS
  44. 8.8.1 SGS Company Information
  45. 8.8.2 SGS Business Overview
  46. 8.8.3 SGS Biocompatibility Testing Revenue and Gross Margin (2021-2026)
  47. 8.8.4 SGS Biocompatibility Testing Product Portfolio
  48. 8.8.5 SGS Recent Developments
  49. 8.9 Nelson Labs
  50. 8.9.1 Nelson Labs Company Information
  51. 8.9.2 Nelson Labs Business Overview
  52. 8.9.3 Nelson Labs Biocompatibility Testing Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Nelson Labs Biocompatibility Testing Product Portfolio
  54. 8.9.5 Nelson Labs Recent Developments
  55. 8.10 Pacific BioLabs
  56. 8.10.1 Pacific BioLabs Company Information
  57. 8.10.2 Pacific BioLabs Business Overview
  58. 8.10.3 Pacific BioLabs Biocompatibility Testing Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Pacific BioLabs Biocompatibility Testing Product Portfolio
  60. 8.10.5 Pacific BioLabs Recent Developments
  61. 8.11 Vantage MedTech
  62. 8.11.1 Vantage MedTech Company Information
  63. 8.11.2 Vantage MedTech Business Overview
  64. 8.11.3 Vantage MedTech Biocompatibility Testing Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Vantage MedTech Biocompatibility Testing Product Portfolio
  66. 8.11.5 Vantage MedTech Recent Developments
  67. 8.12 Cormica Lab (Wickham Micro)
  68. 8.12.1 Cormica Lab (Wickham Micro) Company Information
  69. 8.12.2 Cormica Lab (Wickham Micro) Business Overview
  70. 8.12.3 Cormica Lab (Wickham Micro) Biocompatibility Testing Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Cormica Lab (Wickham Micro) Biocompatibility Testing Product Portfolio
  72. 8.12.5 Cormica Lab (Wickham Micro) Recent Developments
  73. 8.13 CTI
  74. 8.13.1 CTI Company Information
  75. 8.13.2 CTI Business Overview
  76. 8.13.3 CTI Biocompatibility Testing Revenue and Gross Margin (2021-2026)
  77. 8.13.4 CTI Biocompatibility Testing Product Portfolio
  78. 8.13.5 CTI Recent Developments
  79. 8.14 CIRS
  80. 8.14.1 CIRS Company Information
  81. 8.14.2 CIRS Business Overview
  82. 8.14.3 CIRS Biocompatibility Testing Revenue and Gross Margin (2021-2026)
  83. 8.14.4 CIRS Biocompatibility Testing Product Portfolio
  84. 8.14.5 CIRS Recent Developments
  85. 8.15 Shenzhen Advanced
  86. 8.15.1 Shenzhen Advanced Company Information
  87. 8.15.2 Shenzhen Advanced Business Overview
  88. 8.15.3 Shenzhen Advanced Biocompatibility Testing Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Shenzhen Advanced Biocompatibility Testing Product Portfolio
  90. 8.15.5 Shenzhen Advanced Recent Developments
  91. 8.16 Kerbio
  92. 8.16.1 Kerbio Company Information
  93. 8.16.2 Kerbio Business Overview
  94. 8.16.3 Kerbio Biocompatibility Testing Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Kerbio Biocompatibility Testing Product Portfolio
  96. 8.16.5 Kerbio Recent Developments
  97. 8.17 CAS Testing
  98. 8.17.1 CAS Testing Company Information
  99. 8.17.2 CAS Testing Business Overview
  100. 8.17.3 CAS Testing Biocompatibility Testing Revenue and Gross Margin (2021-2026)
  101. 8.17.4 CAS Testing Biocompatibility Testing Product Portfolio
  102. 8.17.5 CAS Testing Recent Developments
  103. 8.18 PONY Medicine
  104. 8.18.1 PONY Medicine Company Information
  105. 8.18.2 PONY Medicine Business Overview
  106. 8.18.3 PONY Medicine Biocompatibility Testing Revenue and Gross Margin (2021-2026)
  107. 8.18.4 PONY Medicine Biocompatibility Testing Product Portfolio
  108. 8.18.5 PONY Medicine Recent Developments
  109. 8.19 Tigermed
  110. 8.19.1 Tigermed Company Information
  111. 8.19.2 Tigermed Business Overview
  112. 8.19.3 Tigermed Biocompatibility Testing Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Tigermed Biocompatibility Testing Product Portfolio
  114. 8.19.5 Tigermed Recent Developments
  115. 8.20 King Rock
  116. 8.20.1 King Rock Company Information
  117. 8.20.2 King Rock Business Overview
  118. 8.20.3 King Rock Biocompatibility Testing Revenue and Gross Margin (2021-2026)
  119. 8.20.4 King Rock Biocompatibility Testing Product Portfolio
  120. 8.20.5 King Rock Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst